Sacituzumab tirumotecan for advanced thymus tumors after prior therapy
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced thymus tumor (one that cannot be removed with surgery or has spread) confirmed by a biopsy.
- Your tumor has grown or returned after at least one previous treatment (like chemotherapy or immunotherapy).
- You have at least one measurable area of tumor that can be tracked with scans.
- You are 18 or older and able to do your daily activities without help (or only need help with heavy work).
- Your blood counts, liver, kidney, and heart function are within safe limits for this therapy.
- You have not had certain types of chemotherapy or antibody-drug treatments before, and any brain metastases are stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called sacituzumab tirumotecan for thymic carcinoma that has spread or come back after prior treatment. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
Hear when a new Thymic Epithelial Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.